Although the classical Child-Pugh Class scoring system is informa

Although the classical Child-Pugh Class scoring system is informative in regards to outcome,141 the most recent iteration of the Mayo score suggested that this model provides more valid survival information than the Child-Pugh Class, particularly in patients early in the course of PSC.142 This model includes age, bilirubin, serum AST and albumin, and history of variceal bleeding as prognostic Depsipeptide ic50 parameters. Using this risk score, patients can be divided into the low, intermediate,

and high-risk groups. A time-dependent prognostic model for the calculation of short-term survival probability in PSC was also developed with data from five European

centers. Bilirubin, albumin, and age at diagnosis of PSC were identified as independent prognostic factors in multivariate analysis.143 A different approach has been used by Dutch investigators based on the earliest available cholangiographic findings. A combination of age and of intrahepatic and extrahepatic scoring obtained at ERC, as a modification from a previous model was strongly predictive of survival.144, 145 Cholangiographic data were also included in a recent study of 273 German patients with PSC.5 Also, a recent study indicates that dominant strictures reduce survival free of liver transplantation further supporting a role for check details cholangiographic information in developing a prognostic model.146 It should be noted that although prognostic

models are useful in predicting outcome selleck compound in patient cohorts, their ability to precisely predict outcomes in an individual patient may be more limited. Recommendations: 27 In patients with PSC, we recommend against the use of prognostic models for predicting clinical outcomes in an individual patient as no consensus exists regarding the optimal model (1B). Effective medical management of PSC has been hindered by uncertainty regarding the pathogenesis of the disease and the factors responsible for its progression. Treatments which are efficacious in other cholestatic liver diseases have been tested in PSC with a limited degree of success.147 Ursodeoxycholic acid (UDCA) is a hydrophilic, dihydroxy bile acid which is an effective treatment of primary biliary cirrhosis (PBC). UDCA has, therefore, also been investigated as a potential candidate for the treatment of PSC. Small pilot trials of UDCA demonstrated biochemical and histological improvement in PSC patients using doses of 10–15 mg/kg/day.11, 148–150 A more substantial trial was published by Lindor et al. in 1997,151 recruiting 105 patients in a double blind placebo controlled trial of 13–15mg/kg of UDCA for 2–5 years.

Comments are closed.